Anti-Obinutuzumab Polyclonal Antibody|抗奥滨尤妥珠单抗多克隆抗体(靶标：奥滨尤妥珠单抗（抗CD20单抗）)
- 货号：RB9TAY257014
- 价格：面议
- 点击：225
产品介绍
产品参数
| 形态 | Liquid |
|---|---|
| 宿主种属 | Rabbit |
| 克隆性 | Polyclonal |
| 抗体亚型 | IgG |
| 纯化方式 | Purified by antigen affinity column. |
| 内毒素水平 | Please contact with the lab for this information. |
| 应用 | ELISA |
| 特异性 | The product is specific for Obinutuzumab. This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays. |
| 靶标 | Rabbit polyclonal to Gazyva. |
| 免疫原 | Obinutuzumab |
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
| 稳定性和储存 | The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
| 产品使用说明 | ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000 |
| 登录号 | CAS: 949142-50-1 |
| 背景信息 | Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system. |
| 备注 | For research use only. |
相关产品: